Nabendu Pore

2.8k citations

26 papers · 2.3k indexed · 1 hit paper · h-index 17

Impact in

Cancer Research top 2%
- Cancer, Hypoxia, and Metabolism
Oncology top 5%

Papers in

Biochemistry 5
- Amino Acid Enzymes and Metabolism 5
Cancer Research 8
- Cancer, Hypoxia, and Metabolism 8

Co-authors: Amit Maity Faramarz Ismail‐Beigi Changhu Chen Alireza Behrooz Donald M. O’Rourke Zibin Jiang George J. Cerniglia Eric J. Bernhard
Journals: Cancer Research (6 papers)Neoplasia (2 papers)International Journal of Radiation Oncology*Biology*Physics (2 papers)Molecular Biology of the Cell (2 papers)PLoS ONE (2 papers)
Partner nations: United States United Kingdom Australia

In The Last Decade

Nabendu Pore

26 papers receiving 2.3k citations

Hit Papers

align trajectories log scale

Regulation of glut1 mRNA by Hypoxia-inducible Factor-1 2001 · 627 citations

Peers

Countries citing papers authored by Nabendu Pore

Since Specialization

Citations

This map shows the geographic impact of Nabendu Pore's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nabendu Pore with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nabendu Pore more than expected).

Fields of papers citing papers by Nabendu Pore

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Nabendu Pore. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nabendu Pore. The network helps show where Nabendu Pore may publish in the future.

Co-authors

The 25 scholars most cited alongside Nabendu Pore, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Nabendu Pore Line = papers co-authored together Nabendu Pore links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Preclinical radiolabeling, in vivo biodistribution and positron emission tomography of a novel pyrrolobenzodiazepine (PBD)-based antibody drug conjugate targeting ASCT2 Nuclear Medicine and Biology ·Christian Wichmann, Ingrid J.G. Burvenich, Nancy Guo, Angela Rigopoulos, Alexander Franklin McDonald, Diana Cao, Graeme O’Keefe, Sylvia Gong, Hui Gan, Fiona E. Scott, Nabendu Pore, Steven Coats, Andrew M. Scott	2023	5
2	Activation of ADAM17 by IL-15 Limits Human NK Cell Proliferation Frontiers in Immunology ·Hemant Kumar Mishra, Kate Dixon, Nabendu Pore, Martin Felices, Jeffrey S. Miller, Bruce Walcheck	2021	19
3	Blocking ADAM17 Function with a Monoclonal Antibody Improves Sepsis Survival in a Murine Model of Polymicrobial Sepsis International Journal of Molecular Sciences ·Hemant Kumar Mishra, Jing Ma, Daniel C. Mendez, Robert Hullsiek, Nabendu Pore, Bruce Walcheck	2020	16
4	Discovery and Development of MEDI7247, a Novel Pyrrolobenzodiazepine (PBD)-Based Antibody Drug Conjugate Targeting ASCT2, for Treating Hematological Cancers Blood ·Nabendu Pore, Kevin Schifferli, Noel R. Monks, Ravinder Tammali, M. Jack Borrok, Elaine M. Hurt, Matt Flynn, Marlon C. Rebelatto, Danielle M. Townsley, Mary Jane Hinrichs, Rakesh Dixit, Steven Coats, Ronald Herbst, David A. Tice	2018	7
5	Anti-ADAM17 monoclonal antibody MEDI3622 increases IFNγ production by human NK cells in the presence of antibody-bound tumor cells Cancer Immunology Immunotherapy ·Hemant Kumar Mishra, Nabendu Pore, Emil F. Michelotti, Bruce Walcheck	2018	42
6	Abstract LB-296: Discovery and development of MEDI7247, a novel Pyrrolobenzodiazepine (PBD)-based antibody drug conjugate targeting ASCT2, for treating hematological and solid cancers Cancer Research ·Nabendu Pore, M. Jack Borrok, Marlon C Rebellato, MaryJane Hinrichs, Kevin Schifferli, Noel R. Monks, Ravinder Tammali, Ronald Herbst, Steven Coats, David A. Tice	2018	1
7	Abstract LB-295: MEDI7247, a novel pyrrolobenzodiazepine ADC targeting ASCT2 with potent in vivo activity across a spectrum of hematological malignancies Cancer Research ·Noel R. Monks, Kevin Schifferli, Ravinder Tammali, M. Jack Borrok, Steven Coats, Ronald Herbst, David A. Tice, Nabendu Pore	2018	6
8	Abstract LB-298: MEDI7247: A first in class antibody drug conjugate targeting ASCT2 in a range of solid tumors Cancer Research ·Kevin Schifferli, Noel R. Monks, Ravinder Tammali, M. Jack Borrok, Matthew Flynn, Elaine M. Hurt, Steven Coats, Ronald Herbst, David A. Tice, Nabendu Pore	2018	6
9	In Vivo Loss of Function Screening Reveals Carbonic Anhydrase IX as a Key Modulator of Tumor Initiating Potential in Primary Pancreatic Tumors Neoplasia ·Nabendu Pore, Sanjoo Jalla, Zheng Liu, Brandon W. Higgs, Claudio Sorio, Aldo Scarpa, Robert E. Hollingsworth, David A. Tice, Emil F. Michelotti	2015	14
10	Epidermal Growth Factor Receptor Inhibition Modulates the Microenvironment by Vascular Normalization to Improve Chemotherapy and Radiotherapy Efficacy PLoS ONE ·George J. Cerniglia, Nabendu Pore, Jeff H. Tsai, Susan M. Schultz, Rosemarie Mick, Regine Choe, Xiaoman Xing, Turgut Durduran, Arjun G. Yodh, Sydney M. Evans, Cameron J. Koch, Stephen M. Hahn, Harry Quon, Chandra M. Sehgal, William M. F. Lee, Amit Maity	2009	104
11	M-CSF Signals through the MAPK/ERK Pathway via Sp1 to Induce VEGF Production and Induces Angiogenesis In Vivo PLoS ONE ·Jennifer M. Curry, Timothy D. Eubank, Ryan D. Roberts, Yijie Wang, Nabendu Pore, Amit Maity, Clay B. Marsh	2008	85
12	EGFR Tyrosine Kinase Inhibitors Decrease VEGF Expression by Both Hypoxia-Inducible Factor (HIF)-1–Independent and HIF-1–Dependent Mechanisms Cancer Research ·Nabendu Pore, Zibin Jiang, Anjali Gupta, George J. Cerniglia, Gary D. Kao, Amit Maity	2006	218
13	Nelfinavir Down-regulates Hypoxia-Inducible Factor 1α and VEGF Expression and Increases Tumor Oxygenation: Implications for Radiotherapy Cancer Research ·Nabendu Pore, Anjali Gupta, George J. Cerniglia, Zibin Jiang, Eric J. Bernhard, Sydney M. Evans, Cameron J. Koch, Stephen M. Hahn, Amit Maity	2006	130
14	HIV Protease Inhibitors Decrease VEGF/HIF-1α Expression and Angiogenesis in Glioblastoma Cells Neoplasia ·Nabendu Pore, Anjali Gupta, George J. Cerniglia, Amit Maity	2006	69
15	Regulation of Histone Deacetylase 4 Expression by the SP Family of Transcription Factors Molecular Biology of the Cell ·Fang Liu, Nabendu Pore, Mijin Kim, Khinh Ranh Voong, Melissa L. Dowling, Amit Maity, Gary D. Kao	2005	42
16	Sp1 Is Involved in Akt-mediated Induction of VEGF Expression through an HIF-1–independent Mechanism Molecular Biology of the Cell ·Nabendu Pore, Shuang Liu, Hui‐Kuo G. Shu, Bin Li, Daphne A. Haas-Kogan, David Stokoe, Julie Milanini, Gilles Pagès, Donald M. O’Rourke, Eric J. Bernhard, Amit Maity	2004	197
17	Regulation of glut1 mRNA by Hypoxia-inducible Factor-1 Journal of Biological Chemistry ·Changhu Chen, Nabendu Pore, Alireza Behrooz, Faramarz Ismail‐Beigi, Amit Maity Hit paper breakdown →	2001	627
18	PTEN mutation cooperates with EGFR activation in human glioblastoma cells to increase VEGF mRNA levels by transactivating an element in the proximal promoter International Journal of Radiation OncologyBiologyPhysics ·Amit Maity, Nabendu Pore, Igor Yu. Kogan, Donald M. O’Rourke	2001	4
19	Epidermal growth factor receptor transcriptionally up-regulates vascular endothelial growth factor expression in human glioblastoma cells via a pathway involving phosphatidylinositol 3'-kinase and distinct from that induced by hypoxia. PubMed ·Amit Maity, Nabendu Pore, Jerry Lee, Don Solomon, Donald M. O’Rourke	2000	246
20	Epidermal growth factor receptor (EGFR) activation interacts additively with hypoxia to upregulate VEGF mRNA expression in human glioblastoma cells International Journal of Radiation OncologyBiologyPhysics ·Amit Maity, J Lee, Nabendu Pore, Donald Solomon, Donald M. O’Rourke	2000	3

About Nabendu Pore

Nabendu Pore is a scholar working on Biochemistry, Cancer Research, Microbiology, Molecular Biology and Genetics, having authored 26 papers that have together received 2.3k indexed citations. Recurring topics across this work include Cancer, Hypoxia, and Metabolism (8 papers), PI3K/AKT/mTOR signaling in cancer (8 papers), Amino Acid Enzymes and Metabolism (5 papers), Angiogenesis and VEGF in Cancer (5 papers), Protein Degradation and Inhibitors (3 papers), Histone Deacetylase Inhibitors Research (3 papers), Glioma Diagnosis and Treatment (3 papers) and Viral-associated cancers and disorders (2 papers). The work is most often cited by research in Cancer Research (1.1k citations), Oncology (614 citations), Molecular Biology (1.4k citations), Genetics (181 citations) and Virology (58 citations). Nabendu Pore has collaborated with scholars based in United States, United Kingdom and Australia. Frequent co-authors include Amit Maity, Faramarz Ismail‐Beigi, Changhu Chen, Alireza Behrooz, Donald M. O’Rourke, Zibin Jiang, George J. Cerniglia, Eric J. Bernhard, Gary D. Kao and Anjali Gupta. Their work appears in journals such as Cancer Research, Neoplasia, International Journal of Radiation Oncology*Biology*Physics, Molecular Biology of the Cell and PLoS ONE.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact